Use of Levetiracetam in Epileptic Dogs with Chronic Kidney Disease: A Retrospective Study

In human medicine, doses of levetiracetam (LEV) are individualized for patients with epilepsy, depending on the status of the patient’s renal function. However, there are not reports on the individualized dosing of LEV for small animals. The aim of this study is to investigate whether a dose adjustm...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	So-Yeon Gim, Woo-Jin Song, Hwa-Young Youn
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	adverse effect chronic kidney disease dogs epilepsy levetiracetam Veterinary medicine SF600-1100
Acceso en línea:	https://doaj.org/article/c927cdfb5bae4d15bb24208d745b37db
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c927cdfb5bae4d15bb24208d745b37db
record_format	dspace
spelling	oai:doaj.org-article:c927cdfb5bae4d15bb24208d745b37db2021-11-25T19:11:58ZUse of Levetiracetam in Epileptic Dogs with Chronic Kidney Disease: A Retrospective Study10.3390/vetsci81102632306-7381https://doaj.org/article/c927cdfb5bae4d15bb24208d745b37db2021-11-01T00:00:00Zhttps://www.mdpi.com/2306-7381/8/11/263https://doaj.org/toc/2306-7381In human medicine, doses of levetiracetam (LEV) are individualized for patients with epilepsy, depending on the status of the patient’s renal function. However, there are not reports on the individualized dosing of LEV for small animals. The aim of this study is to investigate whether a dose adjustment of LEV is needed in dogs with chronic kidney disease (CKD). Patient databases were searched, and 37 dogs with seizures or epilepsy were retrospectively included in this study. Based on pre-existing CKD, patients were divided into a CKD group (<i>n</i> = 20) and a non-CKD group (<i>n</i> = 17). We collected kidney panels before and after LEV treatment. Side-effects were monitored for 1 month after the start of LEV administration. In the CKD group, more dogs developed adverse effects (85%) than in the non-CKD group (52.94%). After LEV administration, an increase in blood urea nitrogen and/or serum creatinine was more often reported in the CKD group than it was in the non-CKD group. Our data indicate that in dogs with seizures or epilepsy with pre-existing CKD, an LEV dose-adjustment is needed. During LEV treatment, CKD patients should be monitored for side-effects and may require laboratory evaluation of renal function.So-Yeon GimWoo-Jin SongHwa-Young YounMDPI AGarticleadverse effectchronic kidney diseasedogsepilepsylevetiracetamVeterinary medicineSF600-1100ENVeterinary Sciences, Vol 8, Iss 263, p 263 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	adverse effect chronic kidney disease dogs epilepsy levetiracetam Veterinary medicine SF600-1100
spellingShingle	adverse effect chronic kidney disease dogs epilepsy levetiracetam Veterinary medicine SF600-1100 So-Yeon Gim Woo-Jin Song Hwa-Young Youn Use of Levetiracetam in Epileptic Dogs with Chronic Kidney Disease: A Retrospective Study
description	In human medicine, doses of levetiracetam (LEV) are individualized for patients with epilepsy, depending on the status of the patient’s renal function. However, there are not reports on the individualized dosing of LEV for small animals. The aim of this study is to investigate whether a dose adjustment of LEV is needed in dogs with chronic kidney disease (CKD). Patient databases were searched, and 37 dogs with seizures or epilepsy were retrospectively included in this study. Based on pre-existing CKD, patients were divided into a CKD group (<i>n</i> = 20) and a non-CKD group (<i>n</i> = 17). We collected kidney panels before and after LEV treatment. Side-effects were monitored for 1 month after the start of LEV administration. In the CKD group, more dogs developed adverse effects (85%) than in the non-CKD group (52.94%). After LEV administration, an increase in blood urea nitrogen and/or serum creatinine was more often reported in the CKD group than it was in the non-CKD group. Our data indicate that in dogs with seizures or epilepsy with pre-existing CKD, an LEV dose-adjustment is needed. During LEV treatment, CKD patients should be monitored for side-effects and may require laboratory evaluation of renal function.
format	article
author	So-Yeon Gim Woo-Jin Song Hwa-Young Youn
author_facet	So-Yeon Gim Woo-Jin Song Hwa-Young Youn
author_sort	So-Yeon Gim
title	Use of Levetiracetam in Epileptic Dogs with Chronic Kidney Disease: A Retrospective Study
title_short	Use of Levetiracetam in Epileptic Dogs with Chronic Kidney Disease: A Retrospective Study
title_full	Use of Levetiracetam in Epileptic Dogs with Chronic Kidney Disease: A Retrospective Study
title_fullStr	Use of Levetiracetam in Epileptic Dogs with Chronic Kidney Disease: A Retrospective Study
title_full_unstemmed	Use of Levetiracetam in Epileptic Dogs with Chronic Kidney Disease: A Retrospective Study
title_sort	use of levetiracetam in epileptic dogs with chronic kidney disease: a retrospective study
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/c927cdfb5bae4d15bb24208d745b37db
work_keys_str_mv	AT soyeongim useoflevetiracetaminepilepticdogswithchronickidneydiseasearetrospectivestudy AT woojinsong useoflevetiracetaminepilepticdogswithchronickidneydiseasearetrospectivestudy AT hwayoungyoun useoflevetiracetaminepilepticdogswithchronickidneydiseasearetrospectivestudy
_version_	1718410182639222784

Use of Levetiracetam in Epileptic Dogs with Chronic Kidney Disease: A Retrospective Study

Ejemplares similares